Sofosbuvir plus velpatasvir for 8 weeks in patients with acute hepatitis C: The HepNet acute HCV-V study

BACKGROUND & AIMS: EASL guidelines recommend 8 weeks of treatment with sofosbuvir plus velpatasvir (SOF/VEL) for the treatment of acute or recently acquired HCV infection, but only 6- and 12-week data are available. Therefore, the aim of this study was to evaluate the safety and efficacy of a sh...

Descripción completa

Detalles Bibliográficos
Autores principales: Maasoumy, Benjamin, Ingiliz, Patrick, Spinner, Christoph D., Cordes, Christiane, Stellbrink, Hans-Jürgen, Schulze zur Wiesch, Julian, Schneeweiß, Stephan M., Deterding, Katja, Müller, Tobias, Kahlhöfer, Julia, Dörge, Petra, von Karpowitz, Maria, Manns, Michael P., Wedemeyer, Heiner, Cornberg, Markus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9957891/
https://www.ncbi.nlm.nih.gov/pubmed/36852107
http://dx.doi.org/10.1016/j.jhepr.2022.100650

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9957891/
https://www.ncbi.nlm.nih.gov/pubmed/36852107
http://dx.doi.org/10.1016/j.jhepr.2022.100650

Ejemplares similares